Systemic lupus erythematosus (SLE)is a chronic autoimmune inflammatory disease of unknown actiology characterized by the presence of several autoanti-bodies and by the anatomical and functional damage of multiple organs. B cells play a central role in the pathogenesis of SLE. Little is known about the frequency of the different B cell subsets in the peripheral blood of SLE patients and whether alteration of these subsets might relate to discase onset and progression. Standard therapeutic strategies. commonly using corticosteroids and immunosuppressive drugs such as azathioprine (AZA), cyclophosphamide (CyC) or methotrexate (MTX),ain at the reduction of discase activity and improvement of the patient's general conditions. Recently, the advances in antibody technology and identification of factors and pathways initiating and maintaining autoimmune disorders allowed the generation of a variety of novel molecules: humanized monoclonal anti-bodies, fusion proteins with antagonistic function and peptibodies,the so called biologic drugs. These molecules are designed to target different B cell subsets and or signalling pathways involved in B-cell activation and in the inflammatory cascade,thus hopefully sparing patients from the side effects duc to generalized immunosuppression.

                                                                                                         [Autoimmun Rev.2007:7(2):143-148]

参考译文

系统性红斑狼疮(SLE)是一种慢性炎症性自身免疫疾病，其病因未明，以自身抗体的出现和多器官结构和功能的损害为特征。其中B细胞在SLE的发病机制中起重要作用。而SLE患者外周血中B细胞亚型的出现频率以及这些亚型与疾病发生发展的相关性并不太清楚。传统的治疗方案包括应用皮质激素和免疫抑制药如硫唑嘌吟(AZA)、环磷酰胺(CyC)、甲氨蝶吟(MTX)，其目的在于控制疾病的活动性，改善患者的一般状况。最近,随着抗体技术的进步以及对引起和维持自身免疫疾病的因子和路径的认识日渐清晰，许多新药物应运而生，包括人化单克隆抗体、具有拮抗功能的融合蛋白和所谓的“生物制剂”。这些药物意在针对不同的B细胞亚型和(或)B细胞活化和炎症级联反应中的不同的信号传导途径，因此有望减少因全身免疫抑制而产生的不良反应。

责任编辑：admin